This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Yamamoto, K.
Right arrow Articles by Kohno, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, K.
Right arrow Articles by Kohno, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2009, p. 3572-3575, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.00176-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Garenoxacin against Streptococcus pneumoniae Mutants with Characterized Resistance Mechanisms{triangledown}

Kazuko Yamamoto,1 Katsunori Yanagihara,2* Kazuyuki Sugahara,2 Yoshifumi Imamura,1 Masafumi Seki,1 Koichi Izumikawa,1 Hiroshi Kakeya,1 Yoshihiro Yamamoto,1 Yoichi Hirakata,3 Shimeru Kamihira,2 and Shigeru Kohno1

Department of Molecular Microbiology and Immunology,1 Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Japan,2 Department of Infection Control and Laboratory Diagnostics, Internal Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan3

Received 8 February 2009/ Returned for modification 19 April 2009/ Accepted 4 May 2009

We evaluated the potency of garenoxacin in selecting resistant Streptococcus pneumoniae mutants by determining its mutant prevention concentration, using strains with and without topoisomerase gene mutations, and compared its potency to that of other quinolones. Garenoxacin had a significantly greater potency against pneumococci, including strains containing topoisomerase mutations. Genetic analysis of the S. pneumoniae mutants created by garenoxacin revealed that the gyrA gene was a primary target of garenoxacin.

* Corresponding author. Mailing address: Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Japan. Phone: 81-95-819-7418. Fax: 81-95-819-7257. E-mail: kyana-ngs{at}umin.ac.jp

{triangledown} Published ahead of print on 18 May 2009.

Antimicrobial Agents and Chemotherapy, August 2009, p. 3572-3575, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.00176-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»